Remember the “Six Million Dollar Man” show on TV? Johns Hopkins and the Department of De...
3 Earnings Movers among Our 4 Charts to Watch
08/09/2017 2:51 am EST
Harry Boxer is watching four stocks breaking out: KITE, KOPN, LOXO and NVCR. He’s the founder of TheTechTrader.com, a live trading room featuring his stock picks, technical market analysis, and live chart presentations.
Here are four stocks looking strong technically and moving on earnings and other news.
Kite Pharma, Inc. (KITE) jumped to a new all-time high of $122.19 Tuesday after releasing quarterly results that beat Wall Street expectations. The stock closed up $6.58, or 5.7%, to $120.13 on 2.1 million shares traded. The cancer therapeutics stock has risen over 160% year-to-date and broke out of its most recent bull flag consolidation pattern on August 5. If the stock clears resistance at its near-term target range of $127-$128, it could go as high as $150.
Kopin Corporation (KOPN) rocketed 57 cents, or 17%, to close at $3.90 on 1.4 million shares traded Tuesday. That volume, which came with the company’s earnings announcement, is more than three times the stock's average volume and the largest since March 13. The wearables technology stock is now positioned to test lateral resistance at the July highs near $4.15, with the target beyond that in the $5-$5.50 range. Short interest of 11 times its average volume could fuel a further move up as shorts cover on a rally.
Loxo Oncology, Inc. (LOXO) rose 21 cents in advance of its earnings announcement Tuesday evening, closing at $73.11. The biotech stock did get as high as $76.15 intraday near lateral resistance. If the stock rises above the resistance level at $76.25-$76.50, the next target is the June highs above $83.
NovoCure Limited (NVCR) emerged from a five-day pullback and ascended above its 21-day moving average, rising 95 cents, or 5.2%, to close at $19.10 on 861,286 shares traded Tuesday. The price action occurred as the biopharma company announced the first national insurance reimbursement, from Austria, for its Optune brain tumor therapy. Price may again test the $21-$21.50 resistance level, and if it clears that, the next target is $27.
Related Articles on STOCKS
Tesla (TSLA) reported revenue of $3.3 billion this quarter versus $2.3 billion last year. For the fu...
Stefanie Kammerman, the Stock Whisperer, to tell you the Whisper of the Week: two energy ETFs, USO, ...
Boeing reported spectacular fourth-quarter results on Jan. 31. Fueled by demand for its 777 wide-bod...